Charles River Laboratories Intl. Inc vs Marathon Digital Holdings Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Marathon Digital Holdings Inc trades at $9.67 (market cap $3.83B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 3.7× Marathon Digital Holdings Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Marathon Digital Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Marathon Digital Holdings Inc for 22 Days on average.
| CRL | MARA | |
|---|---|---|
Market Cap | $14.23B | $3.83B |
Volume | 1,176,885 | 47,742,698 |
Sector | Health | Financials |
52-Week High | $310.77 | $22.84 |
52-Week Low | $149.93 | $6.73 |
Typical Hold Time | 33 Days | 22 Days |
Enterprise Value | $17.06B | $5.87B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $301.79, up 0.5% with strong analyst support (73% buy ratings) and a $305.50 consensus target. The stock shows bullish technical momentum above key support levels, though fundamentals reveal challenges with negative net income margins (-5.96%) and elevated P/E ratio (684.85). Recent quarterly earnings beats and a new 2030 growth strategy provide optimism, but profitability concerns persist amid flat revenue trends.
The outlook balances near-term technical strength against fundamental headwinds. Investment opportunity lies in execution of the 5-7% growth target and $300M savings plan, while risks include sustained negative profitability, high debt levels ($2.24B), and margin pressure. Current price near resistance at $304 suggests limited upside without fundamental improvement.
Marathon Digital Holdings (MARA) trades at $9.65, down 6.85% in the last session, reflecting ongoing volatility. The stock shows mixed signals with bearish technical indicators but positive analyst sentiment. Recent earnings have consistently missed expectations, with Q2 2026 EPS of -$1.60 versus expected $0.17. Despite negative profitability metrics, the company maintains strong analyst coverage with a consensus price target of $13.25, suggesting 37% upside potential from current levels.
MARA presents a high-risk opportunity with significant divergence between fundamental performance and market expectations. While valuation ratios appear attractive (P/E 3.37, EV/EBITDA 3.31), persistent negative earnings and cash flow challenges create substantial execution risk. The stock's performance remains heavily dependent on broader market sentiment and the company's ability to improve operational efficiency amid competitive pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →